ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
-0.02%
US Tech 100
20,325.60
-0.23%
S&P 500
6,021.63
0.57%
US Dollar vs CAD
1.40496
-0.03%
Bitcoin
93,591.63
1.76%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. PharmaTher Holdings Ltd (QB) (PHRRF)

  7. PharmaTher Holdings Ltd (QB) (PHRRF) News

PHRRF

PharmaTher (QB) (PHRRF)

PharmaTher Holdings Ltd (QB)
Date:
Sort by:
 Showing the most relevant articles for your search:USOTC:PHRRF
DateTimeSourceHeadlineSymbolCompany
09/19/20225:31AMTipRanksAnalysts Offer Insights on Healthcare Companies: PharmaTher Holdings Ltd (OtherPHRRF), Rezolute (RZLT) and ADC Therapeutics (ADCT)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
06/15/20224:03AMTipRanksH.C. Wainwright Keeps a Buy Rating on PharmaTher Holdings Ltd (PHRRF)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
11/22/20215:16AMTipRanksH.C. Wainwright Thinks NPharmaTher’s Stock is Going to RecoverUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
11/11/20219:00AMInvestorsHub NewsWirePharmaTher Announces Positive Research Results for Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
11/03/20217:03AMInvestorsHub NewsWirePharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
10/19/20216:07AMInvestorsHub NewsWirePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine ProductsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
10/13/20218:20AMInvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain SyndromeUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
09/21/20219:19AMInvestorsHub NewsWirePharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded FundUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
09/13/20218:03AMInvestorsHub NewsWirePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022USOTC:PHRRFPharmaTher Holdings Ltd (QB)
08/04/20217:15AMInvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral SclerosisUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
07/21/20217:19AMInvestorsHub NewsWirePharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
06/16/202110:14AMInvestorsHub NewsWirePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat DepressionUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
05/25/20217:45AMInvestorsHub NewsWirePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
05/17/20217:02AMInvestorsHub NewsWirePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
04/27/20216:47AMInvestorsHub NewsWirePharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
04/20/20217:00AMInvestorsHub NewsWirePharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical TrialUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
04/15/202110:32AMInvestorsHub NewsWirePharmaTher Provides Update on Psychedelic Product ProgramsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
03/02/20216:34AMInvestorsHub NewsWirePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
02/17/20219:11AMInvestorsHub NewsWirePharmaTher Announces Sale of Psilocybin ProgramUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
02/04/20217:21AMInvestorsHub NewsWirePharmaTher Announces Successful Completion of Pre-IND Meeting with FDAUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
02/01/20217:19AMInvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver KetamineUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
01/19/20217:07AMInvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
 Showing the most relevant articles for your search:USOTC:PHRRF

Your Recent History

BIT
UC2XXF
Unicredit Bank
BIT
P80024
BNP Paribas Issuance
BIT
P1SI93
BNP Paribas Issuance
BIT
P1TR59
BNP Paribas Issuance
BIT
F29238
Vontobel Financial Produ...
COIN
GOTKUSD
GOeureka
BIT
1WE
WeWork
USOTC
TVBCF
Television Broadcast (PK)
BOV
BIYT39Q
BlackRock Institutional ...
BIT
UC74Q7
Unicredit Bank
BIT
P1TM21
BNP Paribas Issuance
BOV
CEAB3F
C&A ON
BIT
UB48FJ
Unicredit Bank
BOV
KLAS3F
Kallas Incorporacoes e C... ON
BOV
CEED3F
CEEE-D ON
BOV
BEWQ39R
MSCI FRANCE DRN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1305.00 only $522.00